Proshares UltraShort Nasdaq Biotech

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Reverse Stock Split

合股

Ex Date: 2026.05.28 (EST), 1-for-2 Reverse Stock Split

513700

159859

516500

SBIO

159837

512290

159892

159849

LABU

588250

ARKG

510660

Ipsen announced findings from the Phase IV DIRECTION trial comparing Dysport and Botox for upper limb spasticity. The results, presented at the ISPRM congress in Vancouver on May 19, 2026, showed Dysport had a similar safety profile to Botox and offered longer-lasting symptom relief.

Unusual Whales

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

China Southern Hang Seng Biotech ETF(QDII)

iShares US Pharma

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Invesco Biotechnology & Genome ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

VG Health

BlackRock, Inc.

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

E Fund Hang Seng SCHK Innovative Drug ETF

Penghua SSE STAR Biology and Medicine ETF

SPDR S&P Biotech

VanEck Biotech ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Minsheng Royal CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

Huaan Hang Seng Biotech ETF

Ark Genomic Revolution ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

The latest Bank of America Fund Manager Survey indicates a record increase in equity allocation among investment professionals, alongside a significant drop in cash levels. This trend follows a strong stock market rally, primarily driven by a few tech sectors, raising concerns about sustainability and the underlying economic fundamentals.

- Bank of America's latest Fund Manager Survey indicates a historic rise in equity allocation among Wall Street investment professionals.  
- This surge is attributed to a significant rally in stocks, particularly in memory, chip, and AI sectors, driven by offside positioning and a historic squeeze.  
- Investors are hopeful that increased debt-funded capital expenditures will continue to benefit these sectors, despite uncertainties regarding their return on investment.

ZeroHedge

VG Growth

iShares Core S&P 500

ProShares Ultra QQQ

Amplify Online Retail ETF

Direxion Semicon Bull 3X

VG S&P 500

iShares Expanded Tech Software Sector ETF

VG S-Cp Grw

VanEck Retail ETF

Invesco QQQ Trust

iShares Semiconductor ETF

SPDR S&P Software

Proshares UltraPro QQQ

VanEck Semiconductor ETF

Schw Us L-Cp Grw

Global X Internet

ISHRS Russ 1000 Growth

SPDR S&P 500

ProShares Online Retail

First Trust NASDAQ-100 Equal Weighted

Global X E-commerce ETF

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

"Sell Signal" Triggered In Latest BofA Fund Manager Survey: Record Surge In Equity Allocation, Plunge In Cash Levels

The Purina Institute is advancing microbiome science in veterinary medicine, focusing on the gut-brain axis and antimicrobial stewardship. Their Microbiome Forum highlighted how gut health influences neurological conditions in pets and emphasized the need for responsible antimicrobial use to protect long-term health. By translating complex research into practical insights, the Institute aims to empower veterinarians to enhance pet health through informed dietary and treatment strategies.

prnewswire

08:59 ETPurina Institute Drives the Conversation on Microbiome Innovation in Veterinary Medicine

UPRO

Barclays warns that the recent record inflow of over $60 billion into U.S. equity funds, driven by FOMO and AI optimism, may lead to a sharp market reversal. Fully invested positions increase vulnerability to downturns on negative news, while bullish leveraged ETF activity has surged, outpacing bearish trades significantly.

- U.S. equity funds saw inflows exceeding $60 billion in the past month, fueled by fear of missing out (FOMO) and optimism surrounding artificial intelligence.  
- Barclays cautions that fully invested positions could leave markets vulnerable to rapid declines due to negative news.  
- Bullish activity in leveraged ETFs has surged, outpacing bearish trades by over three times, approaching levels observed in significant rallies.

Pro UltrPro S&Pro 500

Invesco Nasdaq 100 ETF

Ultr S&P 500 Pro

Barclays

Barclays warns US equity inflows may precede sharp reversal

Kali Therapeutics announced that preclinical data for KT502, a novel CD19 x CD3 T-cell engager, will be presented at the EULAR 2026 Annual Congress in London. KT502 aims to provide deep B-cell depletion for autoimmune diseases with a favorable safety profile. The presentation is scheduled for June 4, 2026, highlighting its potential therapeutic benefits and the company's progress in expanding its clinical pipeline following the initiation of KT501.

07:01 ETKali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress

Microbiotica announced positive results from its phase 1b MELODY-1 trial of MB097 for advanced melanoma, meeting all objectives. The trial involved 41 patients and showed MB097's safety and early efficacy when combined with pembrolizumab. The nine-strain bacterial consortium demonstrated robust engraftment, especially with vancomycin preconditioning. The results support further studies in a broader patient population, aiming to enhance responses to anti-PD-1 therapy.

PharmaTimes

Microbiotica reports positive results for MB097 in advanced melanoma

HBM Holdings Ltd. announced promising preclinical results for LET003, an AI-enabled monoclonal antibody targeting obesity. In animal models, LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, suggesting its potential as a leading obesity therapy. Analysts rate HBM stock as a Buy with a target price of HK$17.00, reflecting confidence in its innovative approach to obesity treatment.

Tip Ranks

HBM HOLDINGS-B

HBM Holdings Unveils Promising Preclinical Data for AI-Enabled Obesity Antibody LET003

Harbour BioMed announced promising preclinical data for LET003, its first AI-enabled drug candidate targeting obesity. LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, while preserving lean mass. The results suggest LET003 could be a best-in-class therapy for obesity, achieving significant fat loss and lean mass improvement at lower doses compared to competitors. The findings were supported by the company's Hu-mAtrIx™ AI platform, indicating strong potential for future development.

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate | ONNVF Stock News

StockTitan

Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate | ONNVF Stock News

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Proshares UltraShort Nasdaq Biotech(BIS.US)

Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

"Sell Signal" Triggered In Latest BofA Fund Manager Survey: Record Surge In Equity Allocation, Plunge In Cash Levels

08:59 ETPurina Institute Drives the Conversation on Microbiome Innovation in Veterinary Medicine

Barclays warns US equity inflows may precede sharp reversal

07:01 ETKali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress

Microbiotica reports positive results for MB097 in advanced melanoma

HBM Holdings Unveils Promising Preclinical Data for AI-Enabled Obesity Antibody LET003

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate | ONNVF Stock News

Regulatory round-up: A month of key FDA approvals for cancer drugs